ストックスクリーナーアプリを入手
0.93
4.12%
-0.04
前日終値:
$0.97
開ける：
$0.96
24時間の取引高:
75,801
Relative Volume:
0.44
時価総額：
$29.18M
収益：
$90,000
当期純損益:
$-23.47M
株価収益率:
-1.2364
EPS:
-0.7522
ネットキャッシュフロー:
$-22.98M
1週間 パフォーマンス:
-5.20%
1か月 パフォーマンス:
-11.43%
6か月 パフォーマンス:
-33.09%
1年 パフォーマンス:
-40.00%
1日の値動き範囲:
$0.92
$0.975
1週間の範囲:
$0.92
$1.05
52週間の値動き範囲:
$0.92
$1.89
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
名前
Actinium Pharmaceuticals Inc
セクター
電話
646-767-3870
住所
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
0.93 | 29.18M | 90,000 | -23.47M | -22.98M | -0.7522 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-02-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 開始されました | B. Riley Securities | Buy |
| 2020-11-05 | 開始されました | Alliance Global Partners | Buy |
| 2017-12-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 再開されました | ROTH Capital | Buy |
| 2017-09-14 | 開始されました | Maxim Group | Buy |
| 2016-08-25 | 開始されました | ROTH Capital | Buy |
| 2016-02-29 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-15 | 開始されました | FBR Capital | Outperform |
| 2014-10-01 | 開始されました | MLV & Co | Buy |
| 2014-07-22 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Actinium Pharmaceuticals Inc (ATNM) 最新ニュース
Actinium Pharmaceuticals (ATNM) Investor presentation Summary - Quartr
Actinium Pharmaceuticals (ATNM) Proxy Filing Summary - Quartr
Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary - Quartr
Actinium Pharmaceuticals (ATNM) 15th Annual LD Micro Invitational 2025 Summary - Quartr
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - AOL.com
Actinium Company Profile & Introduction - Moomoo
ATNM Should I Buy - Intellectia AI
ATNMActinium Pharmaceuticals Inc Earnings - Finviz
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - The National Law Review
ATNM Stockholders Have Opportunity to Lead Actinium Pharmaceutica - The National Law Review
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceut - The National Law Review
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Joi - The National Law Review
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceutical - The National Law Review
Enterprise value to revenue forward of Actinium Pharmaceuticals, Inc. (Delaware) – AMEX:ATNM - TradingView
Price to sales forward of Actinium Pharmaceuticals, Inc. (Delaware) – AMEX:ATNM - TradingView
Price to earnings forward of Actinium Pharmaceuticals, Inc. (Delaware) – AMEX:ATNM - TradingView
Price to book forward of Actinium Pharmaceuticals, Inc. (Delaware) – AMEX:ATNM - TradingView
Actinium Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ATNM) - TradingView
ATNM Forecast — Price Target — Prediction for 2027 - TradingView
Actinium Pharmaceuticals Inc (ATNM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrowed Loss Surpasses Expectations Amid Pipeline ProgressTangible Book Value - dars.gov.et
Actinium Submits NYSE Compliance Plan to Restore Listing - The Globe and Mail
Actinium Pharmaceuticals Inc (ATNM) Institutional Confidence - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actinium Pharmaceuticals Submits NYSE American Compliance Plan After Equity Deficiency Notice - Minichart
Actinium (NYSE: ATNM) details plan to regain NYSE American listing - Stock Titan
Actinium Pharmaceuticals Inc (ATNM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Actinium Pharmaceuticals Inc - TradingKey
Actinium Pharmaceuticals presents expanded ATNM-400 results in NSCLC and prostate cancer - Traders Union
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC - BioWorld News
Actinium presents preclinical data on ATNM-400 for lung cancer - Investing.com UK
Actinium Pharmaceuticals (ATNM) Reveals Promising Preclinical Data for NSCLC Treatment - GuruFocus
Actinium presents preclinical data on ATNM-400 for lung cancer By Investing.com - Investing.com Canada
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PR Newswire
Actinium Pharmaceuticals (ATNM) Appoints New Chief Medical Officer - GuruFocus
Actinium Pharmaceuticals (ATNM) Unveils Key Radiochemistry Findi - GuruFocus
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PR Newswire
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates - PR Newswire
Actinium Pharmaceuticals Appoints Steffen Heeger as CMO Effective June 1, 2026 - geneonline.com
Actinium Pharmaceuticals Presents ATNM-400 Program Updates at SNMMI 2026 and Addresses NYSE American Listing Compliance Notice - Minichart
Actinium Pharmaceuticals Advances with Canadian Patent Allowances for ATNM - GuruFocus
Actinium Highlights New ATNM-400 Data Amid Listing Pressure - TipRanks
Actinium Pharmaceuticals, Inc. (ATNM) announced that two patent applications related to its Actimab-a and Iomab-Act projects have been granted by the Canadian Intellectual Property Office. - Bitget
Actinium Pharmaceuticalsreceives two Canadian patent allowances for Actimab-A and Iomab-Act programs - marketscreener.com
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs - PR Newswire
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice – Company AnnouncementFT.com - Financial Times
Actinium Pharmaceuticals Inc (ATNM) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):